Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up

Journal of Child and Adolescent Psychopharmacology
Yi SuYufeng Wang

Abstract

The purpose of this study was to compare the short-term efficacy, tolerability, and 1-year adherence in Chinese children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with either osmotic release oral system methylphenidate (OROS MPH) or atomoxetine (ATX). Children and adolescents meeting Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV) criteria for ADHD were randomly assigned to receive either OROS MPH (n = 119) or ATX (n = 118). Participants underwent a 1-4 week dose titration period to determine optimal dose, and then were maintained on that dose for 4 weeks (maintenance period). Assessment for efficacy was conducted every week over the titration period and at the end of the maintenance period. The primary efficacy measure was the investigator-rated total ADHD Rating Scale-IV (ADHD-RS-IV) score. Response was further classified as remission (ADHD-RS-IV [18 or 9 items] average score ≤1), robust improvement (ADHD-RS-IV ≥40% decrease in total score), or improvement (≥ 25% decrease in total score) at the end of maintenance period. Medication adherence (taking medication at least 5 days in 1 week) and reasons for nonadherence were evaluated every week over the titration period, ...Continue Reading

References

Nov 1, 1992·Clinical Pharmacology and Therapeutics·I Darmansjah, A Muchtar
Sep 1, 1985·Journal of Child Psychology and Psychiatry, and Allied Disciplines·Y C ShenX L Yang
Feb 2, 2000·Neuroscience and Biobehavioral Reviews·M V Solanto
Apr 13, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·Li YangStephen V Faraone
Apr 22, 2004·Journal of the American Academy of Child and Adolescent Psychiatry·Alice CharachRussell Schachar
Jan 8, 2005·Psychiatric Services : a Journal of the American Psychiatric Association·Edmond H Pi, George M Simpson
Oct 19, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Soyoung Irene LeeJee Wook Choi
Jan 11, 2007·Clinical Therapeutics·Margaret SteeleDeclan M P Quinn
May 11, 2007·Journal of Child and Adolescent Psychopharmacology·Christopher J KratochvilJulie Stoner
Jul 6, 2007·British Journal of Clinical Pharmacology·Yi M CuiStephen D Wise
Feb 2, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joyce A CramerPeter K Wong
Feb 19, 2008·The American Journal of Psychiatry·Jeffrey H NewcornUNKNOWN Atomoxetine/Methylphenidate Comparative Study Group
Jun 2, 2010·Current Pharmaceutical Design·Anil ChackoJodi Z Uderman

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

COMPLY

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.